Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Visiongain Reports | The World Dermatological Market Analysis and Forecasts 2007 to 2022

The World Dermatological Market Analysis and Forecasts 2007 to 2022

Most skin disorders are not fatal but most people are affected globally. The revenue of dermatological market in 2006 was $16bn, which is a 5.1% when compared with 2003. The common skin disorders include acne, dermatitis, psoriasis, rosacea, urticaria and hair loss. Due to the aesthetic awareness increases in Western countries, botulinum toxin and other cosmetic treatments become more and more popular.

The treatment of dermatological disorders are often a cause for concern. Users are keen to benefit from the treatments, often to the point were they overlook possible health concerns. In 2006 September, the FDA launched the iPledge program to prevent birth defects caused by use of isotretinoin during pregnancies. In addition, Roaccutane, an isotretinoin agent for acne, might disrupts serotonin to cause a range of aggression, anger and sleep, according to the study from University of Bath in the UK – this is not the first time studies have shown Roaccutane to be dangerous to some.

This skin disorder report contains:

* The prevalence of skin disorder and the number of cosmetic procedures: It includes the prevalence in the seven major markets.

* The current treatments and future potential treatments as well as drug delivery technologies.

* Current market analysis, including topical and systemic dermatological treatments. The analysis contains the strategic analysis of sales performance, market share and sales forecast to 2012, 2017 and 2022

* Key players analysis, including the analysis of the product portfolio, R&D and the analyses of strategies.

* Porter-Five-Forces Analysis and SWOT analysis to offer the understanding of the strategic issues will impact on dermatological market

Key Market for the Future

Visiongain predicts that the retail market for dermatological treatments will continue to show significant growth for what is an already large market. Corticosteroid agents will still be the main sales drivers to dermatological market whilst botulinum toxin and other cosmetic treatments will be more significant during the forecast period.

Why You Should Buy This Report

• Dermatological treatments is a important therapeutic area which have significant impact to most population globally

• Which treatments are the most efficient for acne, psoriasis and other dermatological conditions? Does any safety concern occur on those treatments? This report will not only answer those questions but also give you the comprehensive view on the patients’ perception for those treatments.

• Corticosteroid agents are widely used on skin disorder due to its potent effect. This report will help you top assess just what impact that this is likely to have.

• Cosmetic procedures become more significant in the recent years, including the treatments of botulinum toxin and hyaluronic acid. Visiongain will tell the market performance and impact of those products.

• Visiongain has taken the latest available financial and prevalence statistics with forecast revenue figures for each dermatological treatment, all the leading products and blockbusters to 2012 or 2022.

• The report contains strategic analysis of the pipeline, in addition, the current market and strategies analysis for key players.

Why You Must Buy This Report?

This report features news, insights, the latest developments and an in depth survey of the pain market with up-to-date analysis as well as tables, graphs and charts. This report is a vital addition to gaining an understanding of this market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain.

Unique benefits to you when you order this report

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Number of pages in the report: 179

Publication date: 26-11-07
Table of Contents
Sample Pages

Price

Single Use Licence $2500.00

Department Licence 5 Users $5000.00

Company-wide Intranet Licence $8750.00

Company over 2500 employees $11750.00

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions